Tcr2 Therapeutics Price To Book vs. Debt To Equity
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
For Tcr2 Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tcr2 Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tcr2 Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tcr2 Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tcr2 Therapeutics over time as well as its relative position and ranking within its peers.
Tcr2 |
Tcr2 Therapeutics Debt To Equity vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Tcr2 Therapeutics's current stock value. Our valuation model uses many indicators to compare Tcr2 Therapeutics value to that of its competitors to determine the firm's financial worth. Tcr2 Therapeutics is rated below average in price to book category among its peers. It is rated fourth in debt to equity category among its peers fabricating about 1.32 of Debt To Equity per Price To Book. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tcr2 Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tcr2 Debt To Equity vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Tcr2 Therapeutics |
| = | 0.22 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Tcr2 Therapeutics |
| = | 0.29 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Tcr2 Debt To Equity Comparison
Tcr2 Therapeutics is currently under evaluation in debt to equity category among its peers.
Tcr2 Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Tcr2 Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tcr2 Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Tcr2 Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Tcr2 Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Tcr2 Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Tcr2 Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tcr2 Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tcr2 Therapeutics' important profitability drivers and their relationship over time.
Use Tcr2 Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.Tcr2 Therapeutics Pair Trading
Tcr2 Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Tcr2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tcr2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tcr2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tcr2 Therapeutics to buy it.
The correlation of Tcr2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tcr2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tcr2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tcr2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Tcr2 Therapeutics position
In addition to having Tcr2 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |